Shanghai Pharmaceuticals (SHA:601607, HKG:2607) obtained a drug registration certificate from China's National Medical Products Administration for isavuconazole sulfate for injection, according to a Tuesday disclosure on the Shanghai bourse.

The drug is used for the treatment of invasive aspergillosis and invasive mucormycosis.